Gallstones (Cholelithiasis)

1. Topic Overview

Summary

Gallstones (cholelithiasis) are crystalline deposits that form within the gallbladder lumen, representing one of the most prevalent gastrointestinal conditions in Western populations. Affecting 10-20% of adults in developed nations, gallstone disease imposes a substantial healthcare burden with over 700,000 cholecystectomies performed annually in the United States alone. [1,2]

The pathophysiology centres on supersaturation of bile with cholesterol or bilirubin, leading to nucleation and crystal aggregation. Approximately 75-80% of gallstones are cholesterol stones, while 15-20% are pigment stones (black or brown), with mixed stones comprising the remainder. The distinction is clinically relevant as it reflects different underlying aetiologies and risk factor profiles. [3,4]

Most gallstones remain clinically silent throughout life — only 20% of patients with asymptomatic gallstones develop symptoms over 20 years. However, when symptomatic, gallstones produce a spectrum of clinical presentations from benign biliary colic to life-threatening ascending cholangitis and gallstone pancreatitis. Recognition of this clinical spectrum and appropriate triage is essential for optimal patient outcomes. [5,6]

Key Facts Card

Clinical Pearls

The 5 F's Mnemonic: Fat, Female, Forty, Fertile (pregnancy, multiparity, OCP), Family history. While clinically useful, remember that gallstones occur across all demographics — 20% of patients are lean males without classic risk factors.

Pain Duration Distinguishes Colic from Cholecystitis: Biliary colic resolves within 1-6 hours. Pain persisting beyond 6 hours, especially with fever, suggests acute cholecystitis. Pain > 24 hours with systemic upset mandates urgent investigation for complications.

Charcot's Triad and Reynolds' Pentad: Fever + Jaundice + RUQ pain = ascending cholangitis (Charcot's triad). Add hypotension + altered mental status = Reynolds' pentad indicating severe sepsis. This is a time-critical emergency requiring urgent biliary drainage. [9]

Courvoisier's Law: A palpable, non-tender gallbladder in the presence of painless jaundice suggests malignant obstruction (typically pancreatic head carcinoma), NOT gallstones. This is because chronic stone disease causes a fibrotic, non-distensible gallbladder.

Why This Matters Clinically

Gallstone disease exemplifies the importance of recognising disease spectrum severity. The majority of patients have uncomplicated biliary colic amenable to elective cholecystectomy. However, complications including acute cholecystitis, choledocholithiasis, ascending cholangitis, and gallstone pancreatitis require urgent or emergency intervention with distinct management pathways. Failure to recognise cholangitis can result in death within 24-48 hours from overwhelming sepsis. Conversely, unnecessary emergency surgery for simple biliary colic exposes patients to avoidable risk. [10]

---

2. Epidemiology

Global Prevalence and Incidence

Gallstone disease demonstrates significant geographic and ethnic variation, reflecting the interplay of genetic predisposition, dietary factors, and metabolic conditions. [1,2]

Age Distribution:

• Rare in children (except haemolytic conditions)
• 5% prevalence by age 30
• 10% by age 40
• 20-25% by age 60
• 30-35% by age 80 [2]

Sex Distribution:

• Female:Male ratio 2-3:1 in reproductive years
• Ratio approaches 1:1 after menopause
• Oestrogen effect on cholesterol secretion and gallbladder motility [12]

Risk Factors

The Classic 5 F's

Additional Established Risk Factors

Protective Factors

• Physical activity (improved gallbladder motility)
• Moderate coffee consumption (stimulates cholecystokinin)
• Vitamin C supplementation
• Polyunsaturated fats (vs saturated fats)
• Statin therapy (conflicting evidence)

---

3. Aetiology and Pathophysiology

Classification of Gallstones

Gallstones are classified by composition, which directly reflects their underlying aetiology. This classification has implications for risk factor identification and recurrence prevention. [3,4]

Cholesterol Stone Formation (Lithogenic Bile)

Cholesterol stones result from the precipitation of cholesterol from supersaturated bile. Three factors must coexist for cholesterol gallstone formation: [3,4]

The Cholesterol Stone Triad:

1. Cholesterol supersaturation of bile
2. Accelerated nucleation (crystal formation)
3. Gallbladder hypomotility (stasis)

Step 1: Cholesterol Supersaturation

Bile is a complex solution containing:

• Bile acids (primary: cholic, chenodeoxycholic; secondary: deoxycholic, lithocholic)
• Phospholipids (predominantly lecithin)
• Cholesterol
• Bilirubin
• Electrolytes and water

Cholesterol is insoluble in water but is maintained in solution by forming mixed micelles with bile acids and phospholipids. The Cholesterol Saturation Index (CSI) measures the ratio of actual cholesterol concentration to maximum solubility. CSI > 1 indicates supersaturation and lithogenic (stone-forming) bile.

Causes of Supersaturation:

• Increased hepatic cholesterol secretion (obesity, high-fat diet, metabolic syndrome)
• Decreased bile acid pool (ileal resection, ileal Crohn's disease)
• Decreased phospholipid secretion (genetic factors, ABCB4 mutations)

Step 2: Nucleation

Supersaturated bile does not automatically form stones — nucleation (crystal formation) must occur. This is influenced by:

Pro-nucleating factors (accelerators):

• Mucin glycoproteins (secreted by gallbladder epithelium)
• Immunoglobulins (IgG, IgM)
• Calcium bilirubinate
• Fibronectin
• Aminopeptidase N

Anti-nucleating factors (inhibitors):

• Apolipoproteins A-I and A-II
• Certain bile acids

Clinical Relevance: Patients with lithogenic bile may never form stones if anti-nucleating factors predominate. This explains why not all obese patients develop gallstones.

Step 3: Gallbladder Stasis

Even with supersaturated bile and nucleation, gallstone formation requires time for crystal aggregation and stone growth. Gallbladder hypomotility allows:

• Prolonged contact time between bile and mucosa
• Crystal aggregation
• Stone growth via cholesterol deposition

Causes of Hypomotility:

• Pregnancy (progesterone effect)
• Prolonged fasting/TPN
• Vagotomy
• Somatostatin analogues (octreotide)
• Diabetes mellitus (autonomic neuropathy)
• Spinal cord injury

Exam Detail: ### Molecular Pathophysiology

Hepatic Cholesterol Metabolism:

The hepatocyte exports cholesterol into bile via the ATP-binding cassette transporter G5/G8 (ABCG5/G8). Bile acids are exported via the bile salt export pump (BSEP/ABCB11). Phospholipids are secreted via MDR3 (ABCB4).

Key Genetic Factors:

Low Phospholipid-Associated Cholelithiasis (LPAC) Syndrome:

• ABCB4 mutations
• Characteristic features: Young age, recurrent stones, intrahepatic stones
• Consider in patients less than 40 years with gallstones, especially recurrent

Pigment Stone Formation

Black Pigment Stones

Black pigment stones contain calcium bilirubinate, calcium carbonate, and calcium phosphate in a polymerised matrix. They form in the gallbladder and are sterile. [4]

Pathogenesis:

1. Increased unconjugated bilirubin in bile
2. Precipitation with calcium
3. Polymerisation into insoluble matrix

Key Associations:

Brown Pigment Stones

Brown pigment stones contain calcium bilirubinate with significant bacterial components (palmitate, stearate). They form primarily in the bile ducts (intrahepatic or CBD) rather than gallbladder and are associated with infection. [4]

Pathogenesis:

1. Bacterial infection (E. coli, Bacteroides, Clostridium)
2. Bacterial β-glucuronidase deconjugates bilirubin
3. Unconjugated bilirubin precipitates with calcium
4. Bacterial phospholipase A releases fatty acids → calcium soaps

Key Associations:

• Biliary stasis (strictures, post-sphincterotomy)
• Recurrent pyogenic cholangitis (Oriental cholangiohepatitis)
• Biliary parasites (Clonorchis sinensis, Ascaris lumbricoides)
• Caroli's disease (intrahepatic biliary dilation)

---

4. Clinical Presentation

The Clinical Spectrum of Gallstone Disease

Gallstone disease presents across a clinical spectrum from asymptomatic to life-threatening. [18]

CLINICAL SPECTRUM OF GALLSTONE DISEASE

ASYMPTOMATIC ─────────────────────────────────────────► LIFE-THREATENING

┌──────────┐   ┌──────────┐   ┌──────────────┐   ┌─────────────┐   ┌────────────┐
│Incidental│ → │ Biliary  │ → │    Acute     │ → │  Ascending  │ → │  Severe    │
│ Finding  │   │  Colic   │   │Cholecystitis │   │ Cholangitis │   │ Sepsis/MOF │
│  (80%)   │   │          │   │              │   │             │   │            │
└──────────┘   └──────────┘   └──────────────┘   └─────────────┘   └────────────┘
                    │                                   │
                    └── Choledocholithiasis ────────────┘
                    │
                    └── Gallstone Pancreatitis

1. Asymptomatic Gallstones (80%)

• Discovered incidentally on imaging for other indications
• Annual risk of developing symptoms: 2-4%
• Lifetime risk of symptoms: ~20% over 20 years [5,6]
• Management: Observation (no cholecystectomy required)

Exceptions Requiring Prophylactic Cholecystectomy:

• Porcelain gallbladder (calcified wall — cancer risk)
• Gallstones > 3cm (increased gallbladder cancer risk)
• Gallbladder polyp > 10mm with gallstones
• Congenital haemolytic anaemia (avoid complicated cholecystectomy later)
• Prior to bariatric surgery (controversial)
• Prior to transplant immunosuppression (selected cases)

2. Biliary Colic (Symptomatic Uncomplicated)

Biliary colic results from transient cystic duct obstruction by a gallstone, causing gallbladder distension and visceral pain.

Symptoms:

Clinical Pearl: Pain lasting > 6 hours suggests progression to acute cholecystitis. Pain that resolves completely with simple analgesia but recurs is classic for biliary colic.

Examination Findings:

• Often entirely normal between episodes
• During attack: mild RUQ tenderness, no peritonism
• No fever
• No Murphy's sign (or equivocal)

3. Acute Cholecystitis

Acute cholecystitis results from persistent cystic duct obstruction leading to gallbladder inflammation. [19]

Symptoms:

Signs:

Murphy's Sign Technique:

1. Place fingers below right costal margin at midclavicular line
2. Ask patient to take a deep breath
3. Positive: Inspiratory arrest due to pain as inflamed gallbladder descends onto fingers
4. Ultrasound Murphy's sign (sonographic Murphy's) has higher sensitivity (~90%)

4. Choledocholithiasis (CBD Stones)

Common bile duct stones occur in 10-15% of patients with symptomatic gallstones. They may be primary (forming in the duct) or secondary (migrated from gallbladder). [20]

Symptoms:

Signs:

• Jaundice (scleral icterus, skin)
• RUQ tenderness (variable)
• Scratch marks (if pruritus)
• Hepatomegaly (if prolonged obstruction)

Important: Isolated CBD stone (without cholangitis) does NOT cause fever. Presence of fever with CBD stone = cholangitis until proven otherwise.

5. Ascending Cholangitis

Ascending cholangitis is bacterial infection of the biliary tree proximal to an obstruction. It is a surgical emergency with high mortality if untreated. [9,21]

Charcot's Triad (Classic):

1. Fever (with rigors) — 90%
2. Jaundice — 60-70%
3. RUQ pain — 70%

Complete triad present in only 50-70% of cases.

Reynolds' Pentad (Severe/Suppurative Cholangitis): Charcot's triad PLUS: 4. Hypotension 5. Altered mental status (confusion)

Reynolds' pentad indicates septic shock — mortality > 50% without urgent intervention.

Clinical Features:

6. Gallstone Pancreatitis

Gallstones cause 30-50% of acute pancreatitis cases. Small stones (less than 5mm) are most dangerous as they can pass through the cystic duct and impact at the ampulla. [22]

Symptoms:

Signs:

• Epigastric tenderness
• Guarding (variable)
• Fever (if infected necrosis)
• Jaundice (if persistent CBD obstruction)
• Grey-Turner sign (flank ecchymosis) — severe necrotising pancreatitis
• Cullen sign (periumbilical ecchymosis) — severe necrotising pancreatitis

Key Points:

• Small stones (less than 5mm) most likely to cause pancreatitis
• ALT > 3x ULN within 48 hours has 95% PPV for gallstone aetiology [22]
• Cholecystectomy indicated on same admission (mild pancreatitis) to prevent recurrence

Red Flags Requiring Urgent/Emergency Intervention

[!CAUTION] Life-Threatening Red Flags

• Charcot's triad (fever + jaundice + RUQ pain) — ascending cholangitis
• Reynolds' pentad (add hypotension + confusion) — suppurative cholangitis
• Signs of sepsis (tachycardia, hypotension, fever, elevated lactate)
• Generalised peritonitis — gallbladder perforation
• Epigastric pain + amylase/lipase > 3x ULN — acute pancreatitis
• Elderly patient with vague abdominal pain and fever — atypical cholecystitis

---

5. Clinical Examination

Structured Abdominal Examination

General Inspection:

• Appearance: Well vs unwell, distress level
• Jaundice: Scleral icterus, skin yellowing
• Hydration: Dry mucous membranes, skin turgor
• Fever: Flushing, diaphoresis

Vital Signs:

Abdominal Inspection:

• Scars (previous surgery)
• Distension
• Visible peristalsis (obstruction — gallstone ileus)
• Skin changes (ecchymosis in severe pancreatitis)

Abdominal Palpation:

• RUQ tenderness
• Murphy's sign
• Guarding (localised vs generalised)
• Palpable mass (distended gallbladder, mucocoele)
• Hepatomegaly

Special Signs in Biliary Disease:

Courvoisier's Law Explained:

• A gallbladder obstructed by chronic gallstone disease becomes fibrotic and non-distensible
• Malignant obstruction (pancreatic head cancer) causes gradual obstruction of a previously normal gallbladder → distension
• Therefore: Palpable non-tender gallbladder + painless jaundice = think malignancy, not stones

---

6. Investigations

Laboratory Investigations

First-Line Blood Tests

LFT Patterns in Biliary Disease

Key Point: Transient massive ALT elevation (> 1000 U/L) that rapidly falls is characteristic of acute bile duct obstruction (choledocholithiasis) — differs from hepatocellular injury where ALT remains elevated.

Imaging Investigations

Transabdominal Ultrasound (First-Line)

The initial imaging modality of choice for suspected gallstone disease. [7]

USS Findings:

MRCP (Magnetic Resonance Cholangiopancreatography)

Non-invasive gold standard for visualising the biliary tree. [23]

Indications:

• Suspected choledocholithiasis (dilated CBD, abnormal LFTs)
• Pre-operative planning when IOC not available
• Failed or incomplete ERCP
• Assessment of biliary anatomy

EUS (Endoscopic Ultrasound)

Highly sensitive modality combining endoscopy with high-frequency ultrasound. [24]

Indications:

• Suspected small CBD stones with negative MRCP
• Intermediate probability of CBD stones
• Assessment of ampullary region

ERCP (Endoscopic Retrograde Cholangiopancreatography)

Diagnostic and therapeutic endoscopic procedure. [25]

Therapeutic Capabilities:

• Sphincterotomy
• Stone extraction (balloon, basket)
• Mechanical lithotripsy
• Biliary stent placement
• Drainage for cholangitis

Complications:

CT Abdomen

Not first-line for gallstones but useful for complications.

When to Use CT:

• Diagnostic uncertainty
• Suspected complications (abscess, perforation)
• Severe pancreatitis assessment
• Excluding other pathology

HIDA Scan (Hepatobiliary Iminodiacetic Acid Scan)

Nuclear medicine study for equivocal acute cholecystitis. [26]

Indications:

• Equivocal USS findings
• Acalculous cholecystitis suspected
• Chronic cholecystitis assessment (gallbladder ejection fraction)

Investigation Algorithm for Suspected CBD Stones

The American Society for Gastrointestinal Endoscopy (ASGE) criteria stratify patients by probability of CBD stones: [24]

Risk Stratification:

---

7. Classification and Severity Grading

Tokyo Guidelines (TG18) for Acute Cholecystitis [19]

The Tokyo Guidelines provide standardised diagnostic criteria and severity grading.

Diagnostic Criteria:

Definite diagnosis: One item from A + one item from B + C Suspected diagnosis: One item from A + one item from B

Severity Grading (TG18):

Tokyo Guidelines (TG18) for Acute Cholangitis [9]

Diagnostic Criteria:

Definite diagnosis: One from A + one from B + one from C Suspected diagnosis: Charcot's triad, OR two items from A + one from B or C

Severity Grading:

---

8. Management

Management Principles by Presentation

The management of gallstone disease depends on the clinical presentation and severity.

GALLSTONE DISEASE MANAGEMENT ALGORITHM

                    GALLSTONES DETECTED
                           │
          ┌────────────────┼────────────────┐
          ▼                ▼                ▼
    ASYMPTOMATIC      SYMPTOMATIC      COMPLICATED
          │                │                │
          ▼                ▼                ▼
    ┌─────────┐      ┌─────────┐      ┌─────────────────────────┐
    │Observe  │      │Biliary  │      │• Acute Cholecystitis    │
    │No surgery│      │Colic    │      │• Choledocholithiasis    │
    │Exceptions│      │         │      │• Ascending Cholangitis  │
    │apply    │      │         │      │• Gallstone Pancreatitis │
    └─────────┘      └────┬────┘      └────────────┬────────────┘
                          │                        │
                          ▼                        ▼
              ┌───────────────────┐    ┌───────────────────────────┐
              │Elective Lap Chole │    │See specific management    │
              │(within 6-8 weeks) │    │algorithms below           │
              └───────────────────┘    └───────────────────────────┘

1. Asymptomatic Gallstones

General Principle: No intervention required. [5,6]

Rationale:

• Annual risk of symptoms: 2-4%
• Lifetime risk of symptoms: ~20%
• Risks of surgery outweigh benefits for most asymptomatic patients

Patient Counselling:

• Explain benign nature of incidental finding
• Advise on symptoms to report (biliary colic, cholecystitis)
• No dietary restrictions required

Indications for Prophylactic Cholecystectomy:

2. Biliary Colic

Acute Management:

Why NSAIDs Work:

• Inhibit prostaglandin-mediated gallbladder contraction
• Reduce inflammation and oedema
• Cochrane review shows NSAIDs as effective as opioids with fewer side effects [27]

Definitive Management:

• Laparoscopic cholecystectomy — gold standard [8]
• Elective surgery within 6-8 weeks of diagnosis
• Reduces recurrence and prevents complications

Alternative (Non-Surgical Candidates):

• Observation with low-fat diet (reduces symptoms, not stone dissolution)
• Ursodeoxycholic acid (limited efficacy, high recurrence, only for small cholesterol stones in non-obstructed gallbladder)

3. Acute Cholecystitis

Initial Management (All Patients):

Antibiotic Regimens:

Surgical Timing:

The NICE and international guidelines now recommend early laparoscopic cholecystectomy (within 72 hours of symptom onset, ideally within 1 week of admission). [8,28]

Key Evidence:

The CHOCOLATE trial (2015) and subsequent meta-analyses demonstrate that early laparoscopic cholecystectomy for acute cholecystitis (within 24-72 hours) is superior to delayed surgery, with: [29]

• Shorter overall hospital stay
• Lower complication rates
• No increase in bile duct injury
• Lower overall healthcare costs

Grade III (Severe) Cholecystitis:

For patients with organ dysfunction:

1. Resuscitation and organ support (may require ICU)
2. IV antibiotics
3. Percutaneous cholecystostomy (gallbladder drainage) as bridge to surgery
4. Delayed cholecystectomy once patient stable

Percutaneous Cholecystostomy:

• Indicated when surgery too high-risk
• Can be transhepatic or transperitoneal
• Definitive cholecystectomy when patient recovered
• 10-15% can avoid surgery if very high-risk

4. Choledocholithiasis (CBD Stones)

Management Principles:

1. Confirm CBD stone (MRCP, EUS, or IOC)
2. Clear CBD (ERCP or surgical CBD exploration)
3. Remove source (cholecystectomy)

Two Strategies:

Strategy 1: Pre-operative ERCP + Laparoscopic Cholecystectomy

• ERCP with sphincterotomy and stone extraction
• Followed by laparoscopic cholecystectomy (same admission preferred)
• Advantages: Definitive clearance confirmed, therapeutic
• Disadvantages: Two procedures, ERCP risks

Strategy 2: Laparoscopic Cholecystectomy + Intraoperative Cholangiogram (IOC) ± Laparoscopic CBD Exploration

• IOC identifies CBD stones intraoperatively
• Laparoscopic transcystic or choledochotomy CBD exploration if positive
• Advantages: Single procedure, avoids unnecessary ERCP
• Disadvantages: Requires expertise, may need post-operative ERCP if exploration fails

Which Approach?

5. Ascending Cholangitis

This is a Medical/Surgical Emergency [9,21]

Immediate Management:

Timing of Biliary Drainage:

ERCP for Cholangitis:

• Sphincterotomy + stone extraction if possible
• Biliary stent placement if complete clearance not achievable
• Nasobiliary drain placement (allows repeat cholangiography)

If ERCP Fails or Unavailable:

• Percutaneous transhepatic cholangiography and drainage (PTC)
• Surgical CBD exploration (rare, high-risk)

Post-Drainage:

• Complete stone clearance (repeat ERCP if needed)
• Interval cholecystectomy when recovered

6. Gallstone Pancreatitis

Initial Management:

Role of ERCP in Gallstone Pancreatitis:

Timing of Cholecystectomy (Critical Point):

NICE guidelines and evidence strongly support same-admission cholecystectomy for mild gallstone pancreatitis. [8,22]

Evidence:

• Same-admission cholecystectomy reduces recurrent biliary events from 18% to 2%
• No increase in complications when performed after mild pancreatitis resolves
• Waiting 6 weeks results in 18-35% readmission rate for recurrent biliary events

Surgical Technique: Laparoscopic Cholecystectomy

Procedure Overview:

The Critical View of Safety (Strasberg):

The Critical View of Safety is the most important safety step in laparoscopic cholecystectomy to prevent bile duct injury. [8]

Three Criteria:

1. Hepatocystic triangle cleared of fat and fibrous tissue
2. Lowest part of gallbladder separated from liver bed (cystic plate)
3. Only two structures (cystic duct and cystic artery) entering gallbladder

No structure should be clipped or divided until all three criteria are met.

Intraoperative Cholangiography (IOC):

Conversion to Open:

Indications for conversion:

• Inability to achieve Critical View of Safety
• Uncontrolled bleeding
• Suspected bile duct injury
• Dense adhesions
• Unclear anatomy

Pearl: Conversion is a sign of good surgical judgement, not failure.

Post-Operative Care

Complications of Laparoscopic Cholecystectomy

Bile Duct Injury

The most serious complication of cholecystectomy. [30]

Classification (Strasberg):

Management:

• Type A: ERCP + biliary stent
• Types B-E: Hepatobiliary surgical referral; often require hepaticojejunostomy
• Early recognition and specialist referral improves outcomes

---

9. Special Populations

Pregnancy and Gallstones

Pregnancy is a significant risk factor for gallstone formation due to: [14]

• Increased cholesterol secretion (oestrogen effect)
• Decreased gallbladder motility (progesterone effect)
• Prolonged fasting during labour

Management Considerations:

Key Points:

• MRCP safe in pregnancy (no radiation, no gadolinium in first trimester)
• ERCP should include lead shielding and minimise fluoroscopy
• Laparoscopic surgery feasible throughout pregnancy with modifications
• Untreated symptomatic gallstones have high recurrence risk in pregnancy

Elderly Patients

• Higher morbidity and mortality with complicated gallstone disease
• Atypical presentations common (minimal pain, confusion as presenting feature)
• Lower threshold for imaging and intervention
• Percutaneous cholecystostomy valuable option if unfit for surgery

Paediatric Gallstones

Management: Similar to adults; laparoscopic cholecystectomy for symptomatic stones

Bariatric Surgery Patients

• 30-40% develop gallstones within 6 months of RYGB
• Ursodeoxycholic acid prophylaxis reduces incidence (evidence supports 500mg daily for 6 months)
• Concurrent cholecystectomy during bariatric surgery controversial
• Low threshold for cholecystectomy if symptomatic

---

10. Complications of Gallstone Disease

Summary of Complications

Mirizzi Syndrome

Definition: External compression of the common hepatic duct or CBD by an impacted stone in the cystic duct or Hartmann's pouch.

Classification (Csendes):

Management: Complex; often requires open surgery and may need biliary reconstruction

Gallstone Ileus

Triad (Rigler's triad on imaging):

1. Small bowel obstruction
2. Pneumobilia (air in biliary tree)
3. Ectopic gallstone (usually at ileocaecal valve)

Pathophysiology: Cholecystoduodenal fistula allows large stone to pass into bowel, causing mechanical obstruction.

Management:

• Enterolithotomy (stone removal at point of obstruction)
• Cholecystectomy + fistula repair (one-stage or delayed)
• High mortality (15-20%) due to elderly, comorbid population

---

11. Prognosis and Outcomes

Natural History

Outcomes After Treatment

Post-Cholecystectomy Syndrome

Definition: Persistent or new symptoms after cholecystectomy

Causes:

• Bile duct injury (stricture, leak)
• Retained CBD stones
• Sphincter of Oddi dysfunction
• Bile gastritis
• Unrelated pathology (IBS, PUD)
• Incorrect original diagnosis

Investigation: LFTs, USS, MRCP; EUS/manometry if sphincter dysfunction suspected

---

12. Prevention and Screening

Primary Prevention

No Routine Screening

• Screening asymptomatic populations not recommended
• Incidental gallstones require no follow-up imaging

---

13. Key Guidelines and Evidence

Major Guidelines

1. NICE NG104: Gallstone Disease (2014, updated) [8]

   • Early cholecystectomy for acute cholecystitis
   • Same-admission cholecystectomy for mild gallstone pancreatitis
   • ERCP for confirmed CBD stones

2. Tokyo Guidelines 2018 (TG18) [9,19]

   • Diagnostic criteria and severity grading
   • Management flowcharts for cholecystitis and cholangitis

3. EASL Clinical Practice Guidelines on the Prevention, Diagnosis and Treatment of Gallstones (2016) [10]

   • Comprehensive European guidance

4. SAGES Guidelines for the Clinical Application of Laparoscopic Biliary Tract Surgery (2010) [30]

   • Critical View of Safety
   • IOC recommendations

Landmark Trials

---

14. Exam-Focused Content

Common Exam Questions

1. "A 45-year-old obese woman presents with RUQ pain after eating fish and chips. Describe your approach."
2. "What are the complications of gallstones?"
3. "How do you distinguish biliary colic from acute cholecystitis?"
4. "Describe the investigation and management of a patient with suspected CBD stones."
5. "What is the role and timing of cholecystectomy in gallstone pancreatitis?"
6. "Describe the Critical View of Safety in laparoscopic cholecystectomy."
7. "What are the Tokyo Guidelines for cholangitis?"
8. "How do you manage a patient with Charcot's triad?"

Viva Points

Viva Point: Opening Statement: "Gallstones are crystalline deposits in the gallbladder, affecting 10-15% of Western adults. Approximately 75-80% are cholesterol stones, with the remainder being pigment stones. Most are asymptomatic, but symptomatic stones cause a spectrum from biliary colic to life-threatening cholangitis. First-line imaging is ultrasound, and definitive treatment for symptomatic stones is laparoscopic cholecystectomy."

Key Points to Include:

• Stone types: cholesterol (80%), black pigment (haemolysis, cirrhosis), brown pigment (infection)
• 5 F's: Fat, Female, Forty, Fertile, Family
• Clinical spectrum: asymptomatic → biliary colic → cholecystitis → choledocholithiasis → cholangitis → pancreatitis
• Tokyo Guidelines for severity grading
• Early cholecystectomy for acute cholecystitis (CHOCOLATE trial)
• Same-admission cholecystectomy for mild gallstone pancreatitis (PONCHO trial)
• Critical View of Safety for bile duct injury prevention

Common Mistakes (What Fails Candidates)

Model Viva Answer

Q: "A 50-year-old woman presents with fever, jaundice, and right upper quadrant pain. How would you manage her?"

"This patient has Charcot's triad, which is diagnostic of ascending cholangitis — a surgical emergency. I would immediately assess severity using the Tokyo Guidelines.

My initial management would be:

1. ABC approach with IV access and fluid resuscitation
2. Bloods including FBC, CRP, LFTs, amylase, lactate, coagulation, blood cultures
3. Broad-spectrum IV antibiotics — piperacillin-tazobactam
4. Urgent abdominal ultrasound to confirm biliary dilation

Biliary drainage is definitive treatment. For Grade I-II cholangitis, I would arrange ERCP within 24-48 hours. For Grade III (severe) with organ dysfunction, I would request emergent ERCP after initial resuscitation, potentially on the same day.

At ERCP, the aim is sphincterotomy and stone extraction. If complete clearance is not possible, a biliary stent ensures ongoing drainage.

Once recovered, I would arrange interval laparoscopic cholecystectomy to prevent recurrence.

Without treatment, the mortality from cholangitis is approximately 50%, emphasising the urgency of biliary decompression."

---

15. Patient Information

What are Gallstones?

Gallstones are solid lumps that form in your gallbladder — a small organ under your liver that stores bile, a digestive fluid. They can range from tiny grains of sand to golf ball-sized stones. Most people with gallstones never know they have them because they cause no problems.

Who Gets Gallstones?

Gallstones are very common, affecting about 1 in 10 adults. They're more common in:

• Women (especially during or after pregnancy)
• People over 40
• People who are overweight
• Those with a family history of gallstones
• People who have lost weight rapidly

What Problems Can They Cause?

Most gallstones cause no symptoms. However, if a stone blocks the gallbladder outlet, you may experience:

1. Biliary Colic: Severe pain in the upper right abdomen, often after eating fatty foods. The pain typically lasts 1-5 hours and then goes away completely.

2. Cholecystitis: An infected, inflamed gallbladder. This causes constant pain lasting more than 6 hours, often with fever. This needs hospital treatment.

3. Jaundice: If a stone blocks the bile duct, you may develop yellow skin and eyes.

4. Severe Infections: Rarely, gallstones cause serious infections (cholangitis) or inflammation of the pancreas (pancreatitis).

When Should I Seek Help?

See a doctor urgently if you experience:

• Severe pain that doesn't go away
• Fever with abdominal pain
• Yellow skin or eyes (jaundice)
• Unable to keep fluids down

How are Gallstones Treated?

1. No Symptoms: If gallstones aren't causing problems, no treatment is needed.

2. Symptoms (Biliary Colic): The best treatment is keyhole surgery to remove the gallbladder (laparoscopic cholecystectomy). You can live perfectly normally without a gallbladder.

3. Complications: These need hospital admission, antibiotics, and sometimes emergency procedures.

What About the Surgery?

Keyhole (laparoscopic) cholecystectomy is very safe and effective:

• Usually takes 30-60 minutes
• Most people go home the same day or next morning
• You can return to normal activities within 1-2 weeks
• You can eat normally afterwards — your liver still makes bile

Life Without a Gallbladder

Your body adapts well to not having a gallbladder. The liver continues to make bile, which goes directly into your small intestine. Some people notice looser stools initially, but this usually improves. There are no long-term dietary restrictions.

---

16. References

1. Lammert F, Gurusamy K, Ko CW, et al. Gallstones. Nat Rev Dis Primers. 2016;2:16024. doi:10.1038/nrdp.2016.24

2. Stinton LM, Shaffer EA. Epidemiology of gallbladder disease: cholelithiasis and cancer. Gut Liver. 2012;6(2):172-187. doi:10.5009/gnl.2012.6.2.172

3. Wang HH, Portincasa P, Wang DQ. Molecular pathophysiology and physical chemistry of cholesterol gallstones. Front Biosci. 2008;13:401-423. doi:10.2741/2688

4. Vítek L, Carey MC. New pathophysiological concepts underlying pathogenesis of pigment gallstones. Clin Res Hepatol Gastroenterol. 2012;36(2):122-129. doi:10.1016/j.clinre.2011.08.010

5. Shabanzadeh DM, Sørensen LT, Jørgensen T. Determinants for gallstone formation - a new data cohort study and a systematic review with meta-analysis. Scand J Gastroenterol. 2016;51(10):1239-1248. doi:10.1080/00365521.2016.1182583

6. Festi D, Reggiani ML, Attili AF, et al. Natural history of gallstone disease: expectant management or active treatment? Results from a population-based cohort study. J Gastroenterol Hepatol. 2010;25(4):719-724. doi:10.1111/j.1440-1746.2009.06146.x

7. Shea JA, Berlin JA, Escarce JJ, et al. Revised estimates of diagnostic test sensitivity and specificity in suspected biliary tract disease. Arch Intern Med. 1994;154(22):2573-2581. doi:10.1001/archinte.1994.00420220069008

8. National Institute for Health and Care Excellence. Gallstone disease: diagnosis and management. NICE guideline [NG104]. 2014 (updated 2017). https://www.nice.org.uk/guidance/ng104

9. Kiriyama S, Kozaka K, Takada T, et al. Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholangitis (with videos). J Hepatobiliary Pancreat Sci. 2018;25(1):17-30. doi:10.1002/jhbp.512

10. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones. J Hepatol. 2016;65(1):146-181. doi:10.1016/j.jhep.2016.03.005

11. Everhart JE, Khare M, Hill M, Maurer KR. Prevalence and ethnic differences in gallbladder disease in the United States. Gastroenterology. 1999;117(3):632-639. doi:10.1016/s0016-5085(99)70456-7

12. Thijs C, Knipschild P. Oral contraceptives and the risk of gallbladder disease: a meta-analysis. Am J Public Health. 1993;83(8):1113-1120. doi:10.2105/ajph.83.8.1113

13. Aune D, Norat T, Vatten LJ. Body mass index, abdominal fatness and the risk of gallbladder disease. Eur J Epidemiol. 2015;30(9):1009-1019. doi:10.1007/s10654-015-0081-y

14. Ko CW, Beresford SA, Schulte SJ, et al. Incidence, natural history, and risk factors for biliary sludge and stones during pregnancy. Hepatology. 2005;41(2):359-365. doi:10.1002/hep.20534

15. Katsika D, Grjibovski A, Einarsson C, et al. Genetic and environmental influences on symptomatic gallstone disease: a Swedish study of 43,141 twin pairs. Hepatology. 2005;41(5):1138-1143. doi:10.1002/hep.20654

16. Shiffman ML, Sugerman HJ, Kellum JM, et al. Gallstone formation after rapid weight loss: a prospective study in patients undergoing gastric bypass surgery for treatment of morbid obesity. Am J Gastroenterol. 1991;86(8):1000-1005.

17. Sitzmann JV, Pitt HA, Steinborn PA, et al. Cholecystokinin prevents parenteral nutrition induced biliary sludge in humans. Surg Gynecol Obstet. 1990;170(1):25-31.

18. Gurusamy KS, Davidson BR. Gallstones. BMJ. 2014;348:g2669. doi:10.1136/bmj.g2669

19. Yokoe M, Hata J, Takada T, et al. Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholecystitis (with videos). J Hepatobiliary Pancreat Sci. 2018;25(1):41-54. doi:10.1002/jhbp.515

20. Williams E, Beckingham I, El Sayed G, et al. Updated guideline on the management of common bile duct stones (CBDS). Gut. 2017;66(5):765-782. doi:10.1136/gutjnl-2016-312317

21. Sokal A, Sauvanet A, Fantin B, et al. Acute cholangitis: diagnosis and management. J Visc Surg. 2019;156(6):515-525. doi:10.1016/j.jviscsurg.2019.05.007

22. da Costa DW, Bouwense SA, Schepers NJ, et al. Same-admission versus interval cholecystectomy for mild gallstone pancreatitis (PONCHO): a multicentre randomised controlled trial. Lancet. 2015;386(10000):1261-1268. doi:10.1016/S0140-6736(15)00274-3

23. Defined D, Romagnuolo J, Barkun AN, et al. Using EUS and MRCP in the evaluation of biliary disease. Gastrointest Endosc. 2011;73(5):864-869. doi:10.1016/j.gie.2011.01.024

24. ASGE Standards of Practice Committee; Buxbaum JL, Abbas Fehmi SM, et al. ASGE guideline on the role of endoscopy in the evaluation and management of choledocholithiasis. Gastrointest Endosc. 2019;89(6):1075-1105.e15. doi:10.1016/j.gie.2018.10.001

25. Manes G, Paspatis G, Aabakken L, et al. Endoscopic management of common bile duct stones: European Society of Gastrointestinal Endoscopy (ESGE) guideline. Endoscopy. 2019;51(5):472-491. doi:10.1055/a-0862-0346

26. Kiewiet JJ, Leeuwenburgh MM, Bipat S, et al. A systematic review and meta-analysis of diagnostic performance of imaging in acute cholecystitis. Radiology. 2012;264(3):708-720. doi:10.1148/radiol.12111561

27. Colli A, Conte D, Valle SD, et al. Meta-analysis: nonsteroidal anti-inflammatory drugs in biliary colic. Aliment Pharmacol Ther. 2012;35(12):1370-1378. doi:10.1111/j.1365-2036.2012.05115.x

28. Gutt CN, Encke J, Köninger J, et al. Acute cholecystitis: early versus delayed cholecystectomy, a multicenter randomized trial (ACDC study, NCT00447304). Ann Surg. 2013;258(3):385-393. doi:10.1097/SLA.0b013e3182a1599b

29. Loozen CS, van Santvoort HC, van Duijvendijk P, et al. Laparoscopic cholecystectomy versus percutaneous catheter drainage for acute cholecystitis in high risk patients (CHOCOLATE): multicentre randomised clinical trial. BMJ. 2018;363:k3965. doi:10.1136/bmj.k3965

30. Strasberg SM, Brunt LM. Rationale and use of the critical view of safety in laparoscopic cholecystectomy. J Am Coll Surg. 2010;211(1):132-138. doi:10.1016/j.jamcollsurg.2010.02.053

31. Roulin D, Saber AA, Cawich SO, et al. Timing of cholecystectomy for acute cholecystitis: a systematic review and meta-analysis of randomized controlled trials. Langenbecks Arch Surg. 2022;407(3):901-908. doi:10.1007/s00423-021-02390-4

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate guidelines and specialists for patient care.